Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.
Q&A: Zymfentra 'gives patients an option' for at-home maintenance therapy of IBD healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
In a systematic review, outcomes such as remission and loss of response were similar between patients with IBD who continued their original biologic and those who switched to a biosimilar.
The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC in patients with inflammatory bowel disease (IBD).LIBERTY-CD and LIBERTY-UC are registrational studies in patients w.